Related Experiment Video
Updated: Jun 8, 2026
Manufacture and Drug Delivery Applications of Silk Nanoparticles
Published on: October 8, 2016
Advanced Nanoparticle-Based Drug Delivery Systems and Their Cellular Evaluation for Non-Small Cell Lung Cancer
Noratiqah Mohtar1, Thaigarajan Parumasivam1, Amirah Mohd Gazzali1
1School of Pharmaceutical Sciences, Universiti Sains Malaysia, Gelugor 11800, Penang, Malaysia.
Abstract:
Lung cancers, the number one cancer killer, can be broadly divided into small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC), with NSCLC being the most commonly diagnosed type. Anticancer agents for NSCLC suffer from various limitations that can be partly overcome by the application of nanomedicines. Nanoparticles is a branch within nanomedicine that can improve the delivery of anticancer drugs, whilst ensuring the stability and sufficient bioavailability following administration. There are many publications available in the literature exploring different types of nanoparticles from different materials. The effectiveness of a treatment option needs to be validated in suitable in vitro and/or in vivo models. This includes the developed nanoparticles, to prove their safety and efficacy. Many researchers have turned towards in vitro models that use normal cells or specific cells from diseased tissues. However, in cellular works, the physiological dynamics that is available in the body could not be mimicked entirely, and hence, there is still possible development of false positive or false negative results from the in vitro models. This article provides an overview of NSCLC, the different nanoparticles available to date, and in vitro evaluation of the nanoparticles. Different types of cells suitable for in vitro study and the important precautions to limit the development of false results are also extensively discussed.
Insights
Nanomedicines, particularly nanoparticles, offer improved delivery for non-small cell lung cancer (NSCLC) treatments. This review covers nanoparticle types and in vitro evaluation methods, highlighting precautions against false results.
Area of Science:
- Oncology
- Nanomedicine
- Pharmacology
Background:
- Non-small cell lung cancer (NSCLC) is the leading cause of cancer mortality, with current treatments facing limitations.
- Nanomedicines, specifically nanoparticles, show promise in enhancing anticancer drug delivery, stability, and bioavailability.
- In vitro models are crucial for validating the safety and efficacy of novel nanomedicine treatments for NSCLC.
Purpose of the Study:
- To provide a comprehensive overview of NSCLC.
- To review various types of nanoparticles developed for NSCLC treatment.
- To discuss the in vitro evaluation of nanoparticles, including suitable cell models and methods to prevent inaccurate results.
Main Methods:
- Literature review of existing publications on NSCLC, nanomedicines, and nanoparticle applications.
- Analysis of different nanoparticle materials and their drug delivery capabilities.
- Discussion of in vitro cell models for nanoparticle efficacy and safety testing.
Main Results:
- Nanoparticles can overcome limitations of conventional NSCLC therapies by improving drug delivery and bioavailability.
- Various nanoparticle types and materials are being explored for their therapeutic potential in NSCLC.
- In vitro models are essential but require careful implementation to avoid false positive or negative outcomes.
Conclusions:
- Nanoparticle-based nanomedicines represent a promising strategy for improving NSCLC treatment efficacy.
- Rigorous in vitro evaluation, considering physiological dynamics and potential biases, is critical for successful nanomedicine development.
- Further research into optimized in vitro models and nanoparticle formulations is warranted for advancing NSCLC therapy.
Related Concept Videos
01:24Modified-Release Drug Delivery Systems: Site-Targeted
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers